Outcome of Board Meeting held today i.e., Friday, 14th November, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Hemo Organic Ltd approved unaudited standalone financial results for Q2 and H1 FY26 (ended September 30, 2025). The statutory auditor issued a Qualified Opinion because no balance confirmations were provided for trade receivables and trade payables. Revenue from operations was negligible at Rs 0.01 lakh in Q2 FY26 versus Rs 0.19 lakh in Q2 FY25, while the company posted a loss after tax of Rs 13.01 lakhs for H1 FY26 against a profit of Rs 16.31 lakhs for FY25. Operating cash flow was negative at Rs (16.81) lakhs, and other equity stands at a deeply negative Rs (373.39) lakhs. The Board deferred a proposal to raise funds via equity/warrants and noted that BSE rejected its waiver for past non-compliance with Regulation 6(1), with the penalty paid on October 30, 2025.
Negative – the qualified audit opinion, near-zero revenue, negative reserves of Rs 373 lakhs, and cash burn raise serious concerns about business continuity and shareholder value. The deferred fund-raising plan could lead to dilution or further stress if executed later.